Contract analysis

I. EXECUTIVE SUMMARY The purpose of this memorandum is to outline a comprehensive strategy for pursuing the resolution of Penterra Pharmaceuticals Corp.'s ("PPC" or the "Company") transfer pricing examination at IRS Appeals, following the issuance of a Notice of Proposed Adjustment ("NOPA") on October 12, 2023, and the corresponding 30-Day Letter issued on November 8, 2023. This memorandum assesses the strengths and

II. BACKGROUND AND PROCEDURAL HISTORY A. The IP Structure and Intercompany Arrangements To provide appropriate context for the analysis that follows, we summarize below the relevant elements of PPC's corporate structure and intercompany arrangements that are at the center of the IRS examination.

1. Formation of PBI and the Cost-Sharing Arrangement Penterra Biopharma Ireland Ltd. ("PBI") was incorporated in Ireland on March 15, 2012, as a wholly owned subsidiary of Penterra Holdings Luxembourg S.à r.l. ("PHL"), which is itself a direct subsidiary of PPC. PHL is treated as a disregarded entity for U.S. federal income tax purposes; accordingly, PBI is treated as a directly owned controlled foreign corporation o

2. Legacy IP License Agreement Separate from the CSA, PBI licenses certain pre-existing pharmaceutical compounds that were developed prior to the CSA's effective date (referred to as "legacy IP" or "pre-2012 compounds") from PPC under a separate intercompany license agreement (the "Legacy IP License"). Under the Legacy IP License, PBI pays a royalty to PPC of 4.5% of net sales of legacy products in the non-Americas t

3. PBI Functions, Assets, and Risks PBI maintains its principal office at approximately 18,000 square feet of office space at Sandyford Business Park, Dublin, Ireland. Since its incorporation in 2012, PBI has grown significantly in both headcount and functional capability. By the end of the examination period, PBI employed approximately 185 employees (up from 52 at inception in 2012), organized across the following f

4. Penterra Manufacturing Ireland Ltd. (PMI) Penterra Manufacturing Ireland Ltd. ("PMI") is PBI's contract manufacturer, operating under a contract manufacturing agreement at a remuneration of cost plus 8%. PMI operates a manufacturing facility in Ringaskiddy, County Cork, Ireland, and employs approximately 620 employees. PMI's operations are limited to manufacturing and does not perform any IP-related functions. PMI

5. Penterra Holdings Luxembourg S.à r.l. (PHL) PHL is an intermediate holding entity organized in Luxembourg. As noted above, PHL is disregarded for U.S. federal income tax purposes and serves as a holding vehicle within the group structure. PHL does not perform any substantive operational functions and is not directly relevant to the transfer pricing issues under examination.

6. Key Products The principal products driving revenue during the examination period include the following: Veritaxol is PPC's flagship oncology product and represents the single largest revenue contributor in both the Americas and non-Americas territories. Imvara, an immunology product, has experienced strong growth since its initial launch in 2015. Cerulon, addressing a rare disease indication, commands premium pri

1. PCT Undervaluation. The IRS asserts that PPC's PCT payment of $312 million substantially understated the arm's-length value of the pre-existing IP contributed to the CSA. The IRS's own valuation, based on Dr. Washburne's DCF analysis at a 7.2% weighted average cost of capital ("WACC"), places the arm's-length PCT payment at $852 million. The IRS uses this asserted undervaluation as the foundation for its adjustmen

2. CSA Cost-Sharing Ratio Adjustment ($235.01 million). The IRS proposes increasing PBI's cost-sharing percentages by 8 to 12 percentage points across all four years. The year-by-year proposed adjustments are set forth in detail in Section III.A below. The IRS asserts that PPC's projections of reasonably anticipated benefits systematically understated the value attributable to U.S.-based R&D contributions, resulting

3. Legacy IP Royalty Rate Adjustment ($188.04 million). The IRS proposes increasing the royalty rate under the Legacy IP License from 4.5% to 11.0% of non-Americas net sales. The IRS's proposed rate is based on a set of allegedly comparable uncontrolled transactions selected by Dr. Washburne, which Calderwood & Harkness and Whitmore believe suffer from material comparability defects.

4. Economic Substance Challenge. The IRS challenges PBI's role as a genuine IP owner and CSA participant, asserting that key DEMPE functions (Development, Enhancement, Maintenance, Protection, and Exploitation of intangible property) remained in the United States throughout the examination period. This argument, if sustained, could potentially support a fundamental recharacterization of the entire intercompany arrang

III. ASSESSMENT OF IRS POSITIONS AND HAZARDS OF LITIGATION This section provides our detailed assessment of each IRS position, evaluating the strengths and weaknesses of both the IRS's arguments and PPC's defenses. This hazards-of-litigation analysis is critical to formulating PPC's settlement posture at Appeals and to advising PPC on the appropriate parameters for settlement authority. A. CSA Cost-Sharing Ratio Adju

1. IRS Position The IRS's cost-sharing ratio adjustment represents the largest single component of the proposed assessment. The IRS proposes increasing PBI's cost-sharing percentage by 8 to 12 percentage points across all four examination years, as set forth in the following table: The IRS's basis for the proposed increase rests on several interrelated assertions. First, the IRS contends that PPC's projections of rea

2. PPC Defense Strengths PPC has several strong arguments against the IRS's proposed cost-sharing ratio adjustment: Contemporaneous RAB Projections Were Reasonable. PPC's cost-sharing ratios were based on contemporaneous projections of reasonably anticipated benefits prepared in accordance with Treas. Reg. § 1.482-7. These projections were prepared at the inception of the CSA in 2012, with periodic updates as require

3. PPC Defense Weaknesses and Litigation Hazards Notwithstanding the strength of PPC's position, we identify the following vulnerabilities: Facial Appeal of Revenue-Split Argument. The IRS's argument that PPC's projected revenue splits were biased toward understating U.S.-source value has some facial appeal, particularly given that the non-Americas share of global revenue did in fact grow over the examination period.

1. IRS Position The IRS proposes increasing the legacy IP royalty rate from 4.5% to 11.0% of non-Americas net sales. The year-by-year proposed adjustments are as follows: The IRS's proposed rate of 11.0% is based on a set of allegedly comparable uncontrolled license agreements selected by IRS Economist Dr. Alan Washburne. The IRS asserts that these CUT comparables demonstrate that a willing licensor and licensee woul

2. PPC Defense Strengths PPC's defense on the royalty rate issue is among its strongest positions: Whitmore CUT Analysis. Whitmore's CUT analysis, prepared by Dr. Vasquez, identified 14 comparable uncontrolled pharmaceutical license agreements through a rigorous and well-documented selection process. The interquartile range of royalty rates in these agreements is 3.1% to 6.8%, with a median of 4.4%. PPC's royalty rat

3. PPC Defense Weaknesses and Litigation Hazards Despite the strength of PPC's CUT analysis, we identify the following risks: Tax Court May Select Its Own Rate. As with the CSA issue, the Tax Court has the authority to select its own royalty rate, which could fall somewhere between PPC's 4.5% and the IRS's 11.0%. While we believe the court would be most likely to select a rate at or near PPC's position, there is some

1. IRS Position The IRS's fourth and final position asserts that PBI lacked sufficient economic substance to justify its role as the IP owner and CSA participant for the non-Americas territories. The IRS contends that key DEMPE functions — Development, Enhancement, Maintenance, Protection, and Exploitation of intangible property — remained in the United States throughout the examination period, and that PBI's activit

2. PPC Defense Strengths PPC's defense on the economic substance issue is its strongest position overall, and is supported by extensive documentary and testimonial evidence: Substantial Employee Base. PBI employed 185 employees by 2020, up from 52 at its inception in 2012. These employees perform genuine, substantive functions across regulatory affairs, medical affairs, commercial strategy, supply chain management, a

3. PPC Defense Weaknesses and Litigation Hazards Notwithstanding the strength of PPC's position on economic substance, we note the following risk factors: Headquarters Influence. The IRS may point to certain strategic decisions — particularly those involving global brand positioning, R&D program prioritization, and major capital investments — that were influenced or approved by PPC headquarters in the United States.

1. Strongest Position — Economic Substance. PBI has robust economic substance, supported by a growing employee base, extensive board governance, significant regulatory expenditures, and independent commercial decision-making. The IRS's economic substance challenge faces significant obstacles.

2. Second Strongest Position — Royalty Rate. PPC's CUT analysis, identifying 14 comparable agreements with a median royalty rate of 4.4%, strongly supports the 4.5% royalty rate. The IRS's proposed 11.0% rate is well above the upper quartile of comparable transactions and relies on comparables with material defects.

3. Most Vulnerable Position — CSA Cost-Sharing Ratios. While PPC's cost-sharing ratios are defensible, there is a modest litigation hazard associated with the projected revenue splits and the Tax Court's broad discretion in evaluating reasonably anticipated benefits. Penalty Position. PPC has a strong reasonable-cause defense under IRC § 6662(e)(3)(B). PPC maintained contemporaneous transfer pricing documentation pre

IV. APPEALS SETTLEMENT POSTURE AND RECOMMENDED POSITIONS A. Settlement Framework The IRS Office of Appeals operates under a hazards-of-litigation standard, meaning that the Appeals Officer assigned to PPC's case will independently evaluate the strengths and weaknesses of both the IRS examination team's positions and PPC's positions, and will seek to fashion a resolution that reflects the genuine hazards of litigation

1. Correlative Adjustment Any settlement must preserve the $42.65 million correlative offset allowed by the examination team to avoid double-counting between the CSA cost-sharing adjustment and the royalty rate adjustment. If the settlement reduces one or both of these adjustments, the correlative offset should be recalculated proportionally to ensure that PPC is not subject to double taxation.

2. GILTI and BEAT Interaction A settlement adjustment will affect PBI's earnings and profits, which may in turn impact PPC's Global Intangible Low-Taxed Income ("GILTI") and Base Erosion and Anti-Abuse Tax ("BEAT") computations for TY 2018–2020 (the years to which GILTI and BEAT apply). Senior Associate Leila Nazari prepared a preliminary analysis of these interactions in October 2022, but this analysis should be upd

3. Competent Authority / Mutual Agreement Procedure (MAP) If the settlement results in material double taxation — i.e., if the income adjustment to PPC is not accompanied by a corresponding reduction in PBI's Irish tax liability — PPC should consider requesting competent authority relief under Article 25 of the U.S.-Ireland Income Tax Treaty. A competent authority request would ask the U.S. and Irish competent author

4. FIN 48 / ASC 740-10 Impact PPC currently maintains an uncertain tax position ("UTP") reserve of $62.4 million under ASC 740-10 (formerly FIN 48) related to the transfer pricing issues under examination. Any settlement will require an adjustment to this reserve. A settlement at PPC's target range (10–15% of the proposed adjustment, or $38.0M–$57.1M) would release a substantial portion of the UTP reserve, resulting

5. Hargrove National Bank Credit Facility PPC maintains a $1.5 billion revolving credit facility with a banking syndicate led by Hargrove National Bank (relationship manager: Christine Bellucci). The credit facility contains material-tax-event covenants that require PPC to notify the lenders in the event of a tax assessment or settlement exceeding certain thresholds. Senior Associate Nazari prepared a preliminary ana

6. SEC Disclosure PPC is a publicly traded company (Nasdaq: PPCA) with SEC reporting obligations. The resolution of the IRS examination will need to be disclosed in PPC's periodic reports, including its 10-K annual report and 10-Q quarterly reports. The UTP reserve adjustment will flow through PPC's tax provision and affect its reported effective tax rate and earnings. We note that Ridgeview Capital Management LP, a

7. State Tax Consequences Any federal income adjustment resulting from the settlement will flow through to PPC's state income tax returns in New Jersey and other states where PPC files. A post-settlement state tax analysis will be required to quantify the incremental state tax liability and to determine whether amended state returns are necessary. Calderwood & Harkness's state tax team can assist with this analysis o

V. PREPARATION OF THE FORMAL PROTEST A. Protest Contents and Structure PPC's formal Protest will be prepared in accordance with the requirements set forth in the 30-Day Letter and IRS Publication 5 (Your Appeal Rights and How to Prepare a Protest). The Protest will contain the following elements: Statement of Facts. A comprehensive factual narrative describing PPC's corporate structure (PPC → PHL → PBI → PMI), the CS

1. The proposed CSA cost-sharing ratio adjustment ($235.01 million);

2. The proposed legacy IP royalty rate adjustment ($188.04 million);

3. The economic substance challenge to PBI's role as IP owner and CSA participant; and

4. The proposed IRC § 6662(e) substantial valuation misstatement penalty ($15.98 million). Law and Argument. The Protest will set forth PPC's legal arguments on each issue, citing the following principal authorities: • IRC § 482 and the arm's-length standard; • Treas. Reg. § 1.482-7 (cost-sharing arrangements, including the PCT and RAB methodology); • Treas. Reg. § 1.482-4 (transfer of intangible property, including

VI. APPEALS CONFERENCE PREPARATION A. Conference Logistics Calderwood & Harkness will request an Appeals conference for late February 2024, with a target date of February 28, 2024. The conference will be requested at the IRS Appeals Office in Manhattan, which is the most convenient location for the full PPC team. A formal letter requesting the conference will be sent to the assigned Appeals Officer in January 2024, p